NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations

par Zhao, Jie, Quan, Haitian, Xie, Chengying, Lou, Liguang
Publié 2014

Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist

par Xie, Chengying, Zhao, Huajun, Bao, Xubin, Fu, Haoyu, Lou, Liguang
Publié dans J Cell Mol Med (2018)

On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry requires activated and phosphorylated Rap1b

par Ribeiro-Neto, Fernando, Urbani, Julie, Lemee, Nicolas, Lou, Liguang, Altschuler, Daniel L.
Publié 2002

A Novel Epac-Rap-PP2A Signaling Module Controls cAMP-dependent Akt Regulation

par Hong, Kyoungja, Lou, Liguang, Gupta, Sandhya, Ribeiro-Neto, Fernando, Altschuler, Daniel L.
Publié 2008

Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodies...

par Sun, Liping, Quan, Haitian, Xie, Chengying, Wang, Lei, Hu, Youhong, Lou, Liguang
Publié 2014

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants

par Zhao, Jie, Quan, Haitian, Xu, Yongping, Kong, Xiangqian, Jin, Lu, Lou, Liguang
Publié dans Cancer Sci (2014)

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia

par Xie, Chengying, He, Ye, Zhen, Mingyue, Wang, Yulan, Xu, Yongping, Lou, Liguang
Publié dans Cancer Sci (2017)

Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin

par Xie, Chengying, Chen, Xiangling, Zheng, Mingyue, Liu, Xiaohong, Wang, Hongbin, Lou, Liguang
Publié dans Oncotarget (2017)

Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition...

par Zhang, Mi, Quan, Haitian, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Publié dans Thorac Cancer (2021)

Aberrant intracellular metabolism of T‐DM1 confers T‐DM1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells

par Wang, Hongbin, Wang, Wenqian, Xu, Yongping, Yang, Yong, Chen, Xiaoyan, Quan, Haitian, Lou, Liguang
Publié dans Cancer Sci (2017)

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

par Xie, Chengying, Wan, Xiaozhe, Quan, Haitian, Zheng, Mingyue, Fu, Li, Li, Yun, Lou, Liguang
Publié dans Cancer Sci (2018)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer

par Wang, Lei, Wang, Quanren, Gao, Mingzhao, Fu, Li, Li, Yun, Quan, Haitian, Lou, Liguang
Publié dans Cancer Sci (2018)

A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation

par Chen, Lu, Quan, Haitian, Xu, Zhongliang, Wang, Hao, Xia, Yuanzhi, Lou, Liguang, Yang, Weibo
Publié dans Nat Commun (2020)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in...

par Wang, Wenqian, Liu, Yang, Zhao, Zhixin, Xie, Chengying, Xu, Yongping, Hu, Youhong, Quan, Haitian, Lou, Liguang
Publié dans Cancer Sci (2016)

X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response

par Zhao, Zhixin, Zhu, Jianming, Quan, Haitian, Wang, Guimin, Li, Bo, Zhu, Weiliang, Xie, Chengying, Lou, Liguang
Publié dans Oncotarget (2016)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer

par Wang, Lei, Wang, Quanren, Xu, Piaopiao, Fu, Li, Li, Yun, Fu, Haoyu, Quan, Haitian, Lou, Liguang
Publié dans Br J Cancer (2020)

An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer

par Li, Hongwen, Yu, Chao, Jiang, Jing, Huang, Changjiang, Yao, Xuejing, Xu, Qiaoyu, Yu, Fang, Lou, Liguang, Fang, Jianmin
Publié dans Cancer Biol Ther (2016)

Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met

par Wang, Lei, Gao, Mingzhao, Tong, Mengya, Xie, Chengying, He, Ye, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang
Publié dans Am J Cancer Res (2018)

Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models

par Long, Fei, He, Ye, Fu, Haoyu, Li, Yun, Bao, Xubin, Wang, Quanren, Wang, Yigang, Xie, Chengying, Lou, Liguang
Publié dans Cancer Sci (2019)

Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants

par Gao, Mingzhao, Zhu, Hongmei, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Quan, Haitian, Wang, Lei, Lou, Liguang
Publié dans Cancer Sci (2019)